ESSEC Business School, 3 avenue Bernard Hirsch, CS 50105 Cergy, 95021 Cergy-Pontoise Cedex, France.
PELyon, 210 avenue Jean Jaurès, 69007 Lyon, France.
Vaccine. 2024 Sep 17;42(22):126039. doi: 10.1016/j.vaccine.2024.06.007. Epub 2024 Jun 8.
The French cancer control strategy 2021-2030 aims to achieve 80 % human papillomavirus (HPV) vaccination coverage. Since 2021, HPV vaccination is also recommended for boys aged 11-14 years, with a catch-up vaccination recommended for unvaccinated adolescents aged ≤19 years. The PAPILLON study used claims data to monitor the evolution of HPV Vaccination Coverage Rate (VCR) in the French population.
The annual HPV VCR was described from 2017 to 2022. Partial vaccination was defined as the dispensing of at least one dose of HPV vaccination. Full scheme vaccination was defined according to the current French recommendations as two or three doses of HPV vaccine over an 18-month period. Annual HPV vaccine initiation rates were estimated on 11-14 and 15-19-year-olds adolescents. Cumulative VCR were estimated on adolescents aged between 11 and 19 years at the time of first vaccination.
Overall, 1,773,900 females and 592,167 males initiated HPV vaccination between 2017 and 2022. Initiations occurred between 11 and 14 years for 67.3 % of females and 62.4 % of males with a median time between the first two doses of 195 days and 190 days, respectively. In girls, the cumulative vaccination rate for the partial scheme vaccination at 15 y.o. increased from 28.1 % in 2017 to 50.9 % in 2022. Similarly, the cumulative vaccination rate for the full scheme vaccination at 16 y.o. increased from 15.5 % in 2017 to 33.8 % in 2022. In 2022, the initiation rates for males were 12.6 % at age 14 and 1.9 % at age 19.
HPV vaccination coverage increased between 2017 and 2022 among girls targeted by the recommendation but remains insufficient. The results of this study show a tentative but promising start to vaccination in boys. This study will monitor the effects of actions taken to improve vaccination, including the extension of vaccination competencies to community pharmacists since end of 2022.
2021-2030 年法国癌症控制战略旨在实现 80%的人乳头瘤病毒（HPV）疫苗接种率。自 2021 年以来，HPV 疫苗也推荐用于 11-14 岁男孩，对于未接种疫苗的 19 岁以下青少年，建议补种疫苗。PAPILLON 研究使用索赔数据监测法国人群 HPV 疫苗接种覆盖率（VCR）的变化。
描述了 2017 年至 2022 年期间 HPV VCR 的年度变化。部分接种定义为至少接种一剂 HPV 疫苗。根据当前法国推荐方案，完全接种定义为在 18 个月内接种两剂或三剂 HPV 疫苗。估计了 11-14 岁和 15-19 岁青少年的年度 HPV 疫苗接种起始率。估计了在首次接种时年龄在 11-19 岁的青少年的累积 VCR。
总体而言，2017 年至 2022 年期间，有 1773900 名女性和 592167 名男性开始接种 HPV 疫苗。女性有 67.3%的人在 11-14 岁开始接种，男性有 62.4%的人在 11-14 岁开始接种，她们的两针之间的中位数时间分别为 195 天和 190 天。在女孩中，2017 年时 15 岁时部分接种方案的累积接种率为 28.1%，到 2022 年增至 50.9%。同样，2017 年时 16 岁时完全接种方案的累积接种率为 15.5%，到 2022 年增至 33.8%。2022 年，14 岁男性的起始接种率为 12.6%，19 岁男性的起始接种率为 1.9%。
2017 年至 2022 年间，推荐接种 HPV 疫苗的女孩的 HPV 疫苗接种覆盖率有所提高，但仍不充分。本研究结果显示，男孩接种疫苗的情况出现了一个有希望的初步迹象。本研究将监测为提高疫苗接种率而采取的行动的效果，包括自 2022 年底以来将疫苗接种权限扩大到社区药剂师。
